Clinical trials: Erythropoiesis Stimulating Agent Pharmacodynamics
- Condition Erythropoiesis Stimulating Agent Pharmacodynamics
- Funder type Industry (pharma, biotech, devices)
Anemia Associated With Chronic Kidney Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with…
- Trial name
- NCT03992066
- Testing
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Akebia Therapeutics
Chemotherapy Induced Anemia, Cancer
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.
- Trial name
- NCT00272662
- Testing
- peginesatide
- Where
- 10 sites in Czechia, Poland and 1 more
- Volunteers
- 60 people
- Sponsor
- Affymax
Anemia, Chronic Kidney Disease
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228436
- Testing
- peginesatide
- Where
- 13 sites in Poland, United Kingdom
- Volunteers
- 139 people
- Sponsor
- Affymax
Anemia, Chronic Kidney Disease
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00109291
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Affymax
Anemia, Chronic Kidney Disease
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
The purpose of this study was to determine the dose ranges of peginesatide administered intravenously or subcutaneously that maintained hemoglobin in participants on dialysis whose hemoglobin values were stable on epoetin (alfa…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00434330
- Testing
- peginesatide
- Where
- 15 sites in Bulgaria, Romania and 1 more
- Volunteers
- 91 people
- Sponsor
- Affymax
Anemia, Chronic Kidney Disease
Peginesatide for Anemia in Chronic Hemodialysis Patients
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228449
- Testing
- peginesatide
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Affymax